Genmab

	30/9 09:50 af E L	, the growth opportunity for TEPEZZA is significant. Our primary focus has been patients with moderate-to severe acute TED, given that this phase lasts on average for two years post-diagnosis. There are approximately 15,000 to 20,000 new patients that enter the market each year and can be treated with TEPEZZA. If left untreated, acute TED transitions into the chronic phase.
	30/9 09:50 af E L	o first, the dramatic efficacy of TEPEZZA; o second, because TED is a painful, vision-threatening disease with debilitating and disfiguring symptoms, patients are highly motivated to seek therapy; and o third, we are significantly investing to drive awareness of TED and TEPEZZA among physicians, patients and advocacy groups – including our highly effective direct-to-consumer television campaigns.
	30/9 09:49 af E L	TEPEZZA is our biologic medicine to threat thyroid eye disease, or TED, and is another example of our strong commercial execution. We delivered one of the most successful rare disease medicine launches ever, despite launching during the pandemic last year. Three factors are driving the strong growth of TEPEZZA as we progress towards our goal to exceed $3.5 billion in peak annual global net sales:
	30/9 09:49 af E L	ok, i'll copy a few of those Horizon remarks:
	30/9 09:45 af StockBull	Tror vi ligger over 80 nu hvis du regner på Jans guiding. om 80 er billigt eller dyrt kommer jo an på potentialet i pipelinen, patentudløb, peaksale m.m og så er det jo bare at forsøge at estimere 5-10 år frem - det er sådanset hvad jeg selv har forsøgt. Ligger sådanset ca. på linie med JPM, Jefferies og GS m.h.t kurstargets - ved ikke lige hvordan MS værdisætter men noget tyder på de har lavere PE
	30/9 09:15 af StockBull	Hold da op hvor heldigt - satte lidt til salg igår til 2800 og de røg i åbningen. Genkøbt i 2767 :-)
	30/9 09:06 af Darvin	Blot en .... ;-)
	30/9 09:06 af Darvin	Jep LLI ikke blot en generel kommentar
	30/9 09:05 af E L	Horizon added 'R&D Day Remarks' on the link i gave earlier, direct (link) maybe that has more
	30/9 08:59 af E L	I did not listen to the Horizon call, but estimate of TEPEZZA peak U.S. annual net sales of >$3B and TEPEZZA ex-U.S. estimate of >$500M peak annual on p14/15 are a bit odd i think, not sure why they consider Europe such a small market then vs US? Many slides on Tepezza , main thing i took away was to expect data for the Chronic Thyroid Eye trial in 2H 2022. Was hoping for a date for start EU penetration.
	30/9 08:58 af E L	@Sukkeralf In the short call JNJ mentioned Rybrevant, Darzalex, Teclistamab and Talquetamab. Mainly on Rybrevant they mentioned their strong commercial strength and expertise in launching these antibodies, pointed again at the combination data with lazertinib, think that it has not yet received enough attention, more on it on the Pharmaceutical Business Review in November 17/18 and mentioned we will see more data on the combo data.
	30/9 08:55 af Bulder	Flere interessante ting i septembernummeret af myelomatosebladet (link)
	30/9 08:24 af Darvin	Jeg er enig med E L i at PE ikke er videre interessant for en aktie som Genmab. Mht om det er “ early stage biotech”, ville jeg sige overvejende ja, men ikke rent. Men Biotech er det! Naturligvis er de på vej mod medico, men er måske 20%medico og 80% Biotech. MEN de er først nu Ved at etablere salgsorg. PE for 21, 22 og 23 er irrelevante. Man skal kigge mindst 3 år frem og regne på den derefter og frem. Og PE nu skulle da gerne ligge skyhøjt over feks NOVO, der ligger over de 30 afh af dagskurs
	30/9 07:46 af Sukkeralf	E L anything good in Horizon or JNJ transcripts ?
	30/9 07:41 af bibob	God morgen :-)
	30/9 07:12 af transalp	Go morgen.. :)
	30/9 06:20 af Helge Larsen/PI-redaktør	God morgen. :-)
	29/9 19:40 af peter12	Spændende artikel om CD3XB7H4 (link) .Det ser ikke ud ti der er andre bsab med B7H4 i klinikken (link)
	29/9 17:47 af E L	Presentation for the Horizon Virtual R&D Day which is going on right now via (link)
	29/9 15:26 af bikube	Har I bemærket, hvor meget U S$ stiger? Mon vi snart igen skal til at budgettere med 6,50?
	29/9 13:31 af Darvin	Nice E L thank’s
	29/9 13:19 af E L	yes, 100%. Brand new in the clinic.
	29/9 13:01 af E L	Natural Killer Cells as Add-on Therapy for Multiple Myeloma Is Showing Promise in the Lab (link)
	29/9 10:59 af E L	Subject must have histologically or cytologically confirmed solid tumor(s) in any of the following selected indications [..] breast cancer, uterine cancer, ovarian cancer, non-small-cell lung cancer [NSCLC], cervical cancer, head and neck squamous cell carcinoma [HNSCC], urothelial cancer; cholangiocarcinoma [CCA]

	29/9 10:57 af E L	380 patients planned in Denmark France Spain United States
	29/9 10:55 af E L	GEN1047 / DuoBody®-CD3×B7H4 in the EU Clinical Trials Register : First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1047 in subjects with malignant solid tumors (link)
	29/9 10:09 af E L	(which fortunately they seem to be making good on now)
	29/9 10:08 af E L	they lost a lot of time during the financial crisis...
	29/9 10:07 af E L	@nohope arbitrary offcourse, but for me they are with only 1 drug on the market themselves now. I would say for another 3-5yrs
	29/9 10:01 af E L	Ideally a patient needs a combo of Teclistamab, Talquetamab and Dara. Then I don't mind if they keep a bit for Halo ;-)
	29/9 10:01 af nohope	Genmab = early stage biotech ?
	29/9 09:59 af E L	@StockBull undisclosed. single digit % for T & T, double that for amivantamab. I use/guess 6% for T & Tand 12% for ami
	29/9 09:55 af E L	I think PE valuation for an early stage biotech is rather useless @Peree , I don't look at it for Genmab
	29/9 09:55 af StockBull	Hvor meget er royalty mon for Teclistamab og Talquetamab ?
	29/9 09:46 af StockBull	Jeg siger jo også 06:01 at Genmab er billig selv om PE er høj :-) jeg regner altid PE 2-3 år forward og PEforward 2023 er ca. 35
	29/9 09:44 af Peree	Undrer mig at EI ikke holder øje med sådan noget
	29/9 09:42 af StockBull	Bundlinien for 2020 var jo ret god og kursen noget lavere så det passer nok med de 28 dengang
	29/9 09:40 af StockBull	Det var nok p.g.a de mega store milestones i 2020
	29/9 09:34 af StockBull	Der må være en fejl. Baseret på Q2 og guiding ligger vi omkring 75. Jan har jo guided profit for 2021 til 2.4 mia så det giver EPS på 36.5kr per aktie og en PE på 75 ved kurs 2775
	29/9 09:29 af Peree	(link) en PE værdi på 28 ?
	29/9 09:28 af Peree	@stockbull - du skriver Genmab har P/E værdi 78, euroenvester skriver i artikel her til morgen:
	29/9 09:27 af henrik48	Store udsving de seneste dage - i dag heldigvis op :-)
	29/9 09:04 af StockBull	mon det er shortlukning fra morgenstunden
	29/9 09:02 af StockBull	Ser ok ud
	29/9 09:01 af Vitus	Du gode gud…der er grønt !!
	29/9 09:00 af E L	Johnson & Johnson (JNJ) Presents at Cantor Fitzgerald 2021 Virtual Global Healthcare Conference (Transcript) (link)
	29/9 08:31 af Plimsoller	God morgen :-)
	29/9 07:39 af Helge Larsen/PI-redaktør	Onsdagens danske avisuddrag med Lego, USA og erhvervsministeriet (link)
	29/9 06:59 af Helge Larsen/PI-redaktør	Asian Markets A Sea Of Red Amid Global Sell-off (link)
	29/9 06:57 af Helge Larsen/PI-redaktør	Asien: Store fald anført af teknologi (link)